The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | Feasibility study of computer vision for quantifying cardiac amyloid burden in biopsies
Taxiarchis Kourelis, MD, Mayo Clinic, Rochester, MN, discusses a feasibility study exploring the potential use of computer vision to quantify cardiac amyloid burden in endomyocardial biopsies. The study aims to develop an artificial intelligence (AI)-based image recognition tool for high-throughput, objective analysis of amyloid deposition. This tool could provide detailed quantification and site-specific breakdowns, potentially correlating amyloid burden with clinical outcomes and aiding research in amyloid-targeting therapies. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding Pfizer
